Shopping Cart
- Remove All
- Your shopping cart is currently empty
Belantamab mafodotin (GSK2857916) is a conjugate of a humanized, targeted monoclonal antibody directed against the B cell maturation antigen (BCMA) and the cytotoxic agent McMMAF, exhibiting anti-myeloma activity [1] [2].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Belantamab mafodotin (GSK2857916) is a conjugate of a humanized, targeted monoclonal antibody directed against the B cell maturation antigen (BCMA) and the cytotoxic agent McMMAF, exhibiting anti-myeloma activity [1] [2]. |
In vitro | Belantamab mafodotin exhibits a high affinity for the human BCMA protein, as indicated by a dissociation constant (K d) of 1 nM [2]. Additionally, it triggers a G2/M phase arrest in multiple myeloma cells, with the extent of the effect dependent on both concentration and exposure duration [2]. Furthermore, belantamab mafodotin significantly enhances the phagocytosis of multiple myeloma cells by macrophages derived from macrophage colony-stimulating factor (M-CSF) stimulated monocytes [2]. |
In vivo | Belantamab mafodotin significantly enhances survival relative to the vehicle in mice with OPM2 tumors [2]. |
Alias | GSK2857916, Belantamab mafodotin-blm |
Cas No. | 2050232-20-5 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.